Weber M M, Lang J, Abedinpour F, Zeilberger K, Adelmann B, Engelhardt D
Medizinische Klinik II, Klinikum Grosshadern, Ludwig-Maximilians-Universität München.
Clin Investig. 1993 Nov;71(11):933-8. doi: 10.1007/BF00185607.
The narcotic agent etomidate and the antimycotic drug ketoconazole are known to block steroid biosynthesis in man. To study the different effects of these imidazole derivatives on human adrenal steroid biosynthesis we incubated slices of human adrenal glands with 3H-labeled precursors and increasing concentrations of etomidate or ketoconazole (0-2000 microM). After extraction the labeled metabolites were separated by thin-layer chromatography and quantified by scintillation counting. Etomidate inhibited most potently 11 beta-hydroxylase activity by suppressing the formation of corticosterone from 11-deoxycorticosterone to 1% of control [50% inhibitory concentration (IC50) 0.03 microM] while ketoconazole suppressed 11 beta-hydroxylase to only 39% of control activity (IC50 15 microM). Ketoconazole however, most potently blocked the conversion of 17 alpha-hydroxy-progesterone to androstenedione by C17,20-desmolase to about 15% of control activity (IC50 1 microM) while etomidate showed a much weaker effect on this enzyme with a suppression to 50% of C17,20-desmolase control activity at a concentration of 380 microM. Both imidazole drugs showed a similar strong inhibitory effect on the activity of 17 alpha-hydroxylase (IC50 6-18 microM) and 16 alpha-hydroxylase (IC50 4-8 microM) and did not affect 21-hydroxylase. These in vitro data indicate a predominant inhibitory effect of etomidate on corticosteroid biosynthesis by relative selective inhibition of 11 beta-hydroxylase and of ketoconazole on the adrenal androgen biosynthesis by a predominant inhibition of C17,20-desmolase. This differential inhibitory effect of etomidate and ketoconazole on human steroid biosynthesis may be of clinical importance for a possible therapeutic use of these imidazole derivatives in endocrine disorders.
已知麻醉剂依托咪酯和抗真菌药物酮康唑可阻断人体中的类固醇生物合成。为研究这些咪唑衍生物对人肾上腺类固醇生物合成的不同影响,我们将人肾上腺切片与3H标记的前体以及浓度不断增加的依托咪酯或酮康唑(0 - 2000微摩尔)一起孵育。提取后,通过薄层色谱法分离标记的代谢产物,并通过闪烁计数进行定量。依托咪酯通过将11 - 脱氧皮质酮生成皮质酮的过程抑制至对照的1% [50%抑制浓度(IC50)0.03微摩尔],从而最有效地抑制11β - 羟化酶活性,而酮康唑仅将11β - 羟化酶抑制至对照活性的39%(IC50 15微摩尔)。然而,酮康唑最有效地阻断了C17,20 - 裂解酶将17α - 羟基孕酮转化为雄烯二酮的过程,抑制至对照活性的约15%(IC50 1微摩尔),而依托咪酯对该酶的作用则弱得多,在浓度为380微摩尔时,将C17,20 - 裂解酶对照活性抑制至50%。两种咪唑类药物对17α - 羟化酶(IC50 6 - 18微摩尔)和16α - 羟化酶(IC50 4 - 8微摩尔)的活性均表现出类似的强烈抑制作用,且不影响21 - 羟化酶。这些体外数据表明,依托咪酯通过相对选择性抑制11β - 羟化酶对皮质类固醇生物合成具有主要抑制作用,而酮康唑通过主要抑制C17,20 - 裂解酶对肾上腺雄激素生物合成具有主要抑制作用。依托咪酯和酮康唑对人类固醇生物合成的这种差异抑制作用对于这些咪唑衍生物在内分泌疾病中的可能治疗用途可能具有临床重要性。